These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 34971577)
1. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577 [TBL] [Abstract][Full Text] [Related]
2. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease. Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489 [TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Locatelli F; Antmen B; Kang HJ; Koh K; Takahashi Y; Kupesiz A; Dias Matos MGA; Chopra Y; Bhat S; Im HJ; Güngör T; Lu MY; Stefanelli T; Rosko C; St Pierre A; Burock K; Smith Y; Sinclair K; Diaz-de-Heredia C Lancet Haematol; 2024 Aug; 11(8):e580-e592. PubMed ID: 39002551 [TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Schroeder MA; Khoury HJ; Jagasia M; Ali H; Schiller GJ; Staser K; Choi J; Gehrs L; Arbushites MC; Yan Y; Langmuir P; Srinivas N; Pratta M; Perales MA; Chen YB; Meyers G; DiPersio JF Blood Adv; 2020 Apr; 4(8):1656-1669. PubMed ID: 32324888 [TBL] [Abstract][Full Text] [Related]
5. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843 [TBL] [Abstract][Full Text] [Related]
6. Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J; Gandhi I; Kasikis S; Gleich S; Hexner E; Hoepting M; Kapoor U; Kowalyk S; Kwon D; Langston A; Mielcarek M; Morales G; Özbek U; Qayed M; Reshef R; Rösler W; Spyrou N; Young R; Chen YB; Ferrara JLM; Levine JE Blood; 2023 Feb; 141(5):481-489. PubMed ID: 36095841 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Russo D; Schmitt M; Pilorge S; Stelljes M; Kawakita T; Teal VL; Haber B; Bopp C; Dadwal SS; Badshah C Lancet Haematol; 2024 Feb; 11(2):e127-e135. PubMed ID: 38142695 [TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762 [TBL] [Abstract][Full Text] [Related]
10. Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. Wang Y; Liu QF; Wu DP; Xu ZL; Han TT; Sun YQ; Huang F; Fan ZP; Xu N; Chen F; Zhao Y; Kong Y; Mo XD; Xu LP; Zhang XH; Liu KY; Huang XJ BMC Med; 2024 Apr; 22(1):176. PubMed ID: 38664766 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants. Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750 [TBL] [Abstract][Full Text] [Related]
12. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675 [TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936 [TBL] [Abstract][Full Text] [Related]
17. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
18. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376 [TBL] [Abstract][Full Text] [Related]
19. Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease. Chen X; Xun Z; Yuska B; McGee R; Yeleswaram S J Clin Pharmacol; 2023 May; 63(5):622-632. PubMed ID: 36601737 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]